While biosimilars have made significant inroads into the European marketplace, there remain hurdles to the adoption of these lower-cost drugs, especially in lower-income nations; external reference pricing can mean that drugs are priced to wealthier European countries’ financial capabilities, and manufacturers’ launch strategies may bring biosimilars to nations with the greatest market potential first.
While biosimilars have made significant inroads into the European marketplace, there remain hurdles to the adoption of these lower-cost drugs, especially in lower-income nations; external reference pricing can mean that drugs are priced to wealthier European countries’ financial capabilities, and manufacturers’ launch strategies may bring biosimilars to nations with the greatest market potential first.
A paper newly published in Biomed Research International describes factors that limit the increased use of biosimilars in 10 nations where financial constraints are greater than they are elsewhere in Europe.
In 2015, using a survey that collected feedback from 2 policy experts (1 from a public agency and 1 from a private entity) each in Bulgaria, Czech Republic, Hungary, Kazakhstan, Latvia, Lithuania, Poland, Romania, Russia, and Slovakia, researchers sought to understand the policy environment in each country to the eventual uptake of trastuzumab, rituximab, and infliximab biosimilars.
Across the countries, a number of key barriers to patient access to biologic therapy were identified, including:
The respondents said that the key benefit of biosimilars would be increased access to treatment; cost savings and the increased number of treatment options were mentioned only as secondary benefits.
The participants identified the following issues as limiting patient access to biosimilars:
While the authors note that the generalizability of their findings are limited by the small number of policy experts engaged in each country’s survey, they write that their findings indicate a need for more affordable biologic therapies in these less wealthy nations.
“Policy makers have to take a strategic approach to increase societal benefit from biosimilar medicines,” conclude the authors. “Relying on free-market incentives may not be strong enough; hence, active government interventions instead of ‘passive disinvestment’ policies are needed to correct for current access limitations.”
Reference
Inotai A, Csandi M, Petrova G, et al. Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts [published online January 10, 2018]. Biomed Res Int. doi: 10.1155/2018/9597362.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.